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Background
Live Attenuated SIV confers potent protection against
wild-type SIV challenge. However the mechanism of
protection is poorly understood and does not appear to
correlate with adaptive immune responses. We have
constructed a novel conditionally live SIVmac239 var-
iant that replicates exclusively when doxycycline(dox) is
administered [1,2]. This SIV-rtTA variant is used to
investigate the role of duration and persistence of vacci-
nation in protection against homologous and heterolo-
gous wild-type virus challenge.
Materials and methods
Mauritian cynomolgus macaques were vaccinated with
SIV-rtTA and subsequently challenged with the hetero-
logous wild-type virus SIVsmE660. Indian rhesus maca-
ques were vaccinated with SIV-rtTA and subsequently
challenged with wild-type SIVmac239.
Results and conclusions
In naive cynomolgus macaques, SIVsmE660 establishes
high peak and steady-state viraemia. After 20 weeks vac-
cination with SIV-rtTA in the presence of dox, 6/6 ani-
mals were protected against SIVsmE660. By contrast
only 1/6 animals were protected after 3 weeks vaccina-
tion in the presence of dox. The role of persisting vac-
cine virus replication was investigated by vaccinating for
3 weeks with SIV-rtTA in the presence of dox, removing
doxfor 17 weeks and subsequent challenging with
SIVsmE660. In this group, 3/6 vaccinates were protected
against detectable infection with SIVsmE660 in the
periphery. These data demonstrate that live attenuated
SIV can protect against a vigorously replicating, hetero-
logous challenge virus (SIVsmE660) and that a longer
duration of vaccination is beneficial, even when the vac-
cine-virus is apparently ‘switched-off’.
Vaccination of rhesus macaques with the same SIV-
rtTA vaccine for 6 months in the presence of dox pro-
tected only 2/8 vaccinates against homologous challenge
with wild-type SIVmac239. Remarkably, both protected
animals demonstrated more persistent viral load kinetics
upon vaccination, which confirms that prolonged repli-
cation of the vaccine virus improves protection.
Sequence recovery of SIV-rtTA indicated an absence of
mutations in the rtTA gene that would impact on doxy-
cycline dependency. The presence of only minimal
changes elsewhere indicated that SIV-rtTA was geneti-
cally stable in vivo. Since the genetics and antigenic
relatedness of vaccine and challenge virus does not
appear to predict the outcome of these vaccine studies,
the kinetics and relative persistence of vaccine virus
replication and the role of innate anti-retroviral
responses are being evaluated.
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